The global blockbuster oncology brands market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing adoption of cancer immunotherapies in developed regions coupled with constant development of indications with accelerated approvals.
Biomarker based treatment option for patient increases the complexity of the cancer treatment for doctors. Inside the cancer types for the division of patients these therapies are most important. On the other hand, many recently introduced therapies for blockbuster oncology brands are progressively serving large number of patient, targeting approvals in the frontline settings, and proceeding beyond current biomarker niches.
The U.S. Food and Drugs Administration (FDA) approved, Zejula, for its use. Zejula is a fourth line of treatment on recurrent ovarian cancer. Large number of therapies either got front line treatment approval or in the process of assembling clinical trial evidences for approval. Complete survival for long term and progression-free risk evidence are supporting safety and efficiency of these therapies which aids the market in coming years. The blockbuster oncology brands market is very competitive. In particular disease segments manufacturer dominated the brand leadership. For instance, Roche, Merck & Co. (Merck), and Bristol-Myers-Squibb (BMS) are competing in the Non-small-cell lung carcinoma (NSCLC) patient subclass.
Although it is blockbuster therapies in its portfolio, Roche holds less share in lung cancer segment which is around 10% but in breast cancer segment it holds more than 40% share. To increase the presence and gaining competitive advantage among other blockbuster oncology therapies, market players are majorly increasing indications and achieving mixture of regimen clinical trials. Costly immunotherapies are slowing down the market. Companies are submitting the negotiations related to price with regulatory agencies or decline availability of immunotherapy in some countries. Many market players are presenting deals in emerging economies.
The report on the global blockbuster oncology brands market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Blockbuster Oncology Brands Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Brands (Opdivo, Revlimid, Zejula, Keytruda, Perjeta, Ibrance, Tecentriq, Gazyva, Tagrisso, Darzalex, and Imbruvica), Indications (Lung Cancer, Lymphoma, Multiple Myeloma, Breast cancer, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Bristol Myers Squibb.; Merck& Co.; Pfizer, Inc.; Roche, Ltd; AstraZeneca Plc.; and Tesaro, Inc.
Opdivo segment is projected to hold a key market share
On the basis of brands, the blockbuster oncology brands market is segmented into Opdivo, Revlimid, Zejula, Keytruda, Perjeta, Ibrance, Tecentriq, Gazyva, Tagrisso, Darzalex, and Imbruvica. Opdivo, Revlimid, And Keytruda collectively held the largest market share. The Opdivo segment is expected to holds a key share of the market during the forecast period due to their rise in adoption for treatment of lung cancer and wide availability across globe. Various clinical trials are ongoing for rising its use in different indications such as glioblastoma, solid tumors, and prostate cancer.
Lung cancer segment is expected to grow at a rapid pace
Based on indications, the blockbuster oncology brands market is segmented into lung cancer, lymphoma, multiple myeloma, breast cancer, and others. The lung cancer segment is anticipated to expand at a rapid pace during the forecast period. It has lower survival rate and is major cause of cancer death burden each year. In many cases, at an advanced stage the lung cancer is diagnosed. Presently, Opdivo, Keytruda, Tecentriq, and Tagrisso are some first or second line of treatment options for lung cancer. Recently, Keytruda and Opdivo are approved by FDA and increasing use of blockbuster brands for frontline therapy. Also, other therapies are going under trials for enhancement for including huge targeted population which is projected to fuel the segment growth.
On the other hand, breast cancer is expected to account for a key share of the market in the coming years. It is related to high mortality and presence among women. The FDA had approved Perjeta and Ibrance immunotherapies for treating the breast cancer. For the treatment of HER2+ breast cancer, Perjeta is approved and for HR+/HER2- type of breast cancer Ibrance is approved. HR+/HER2- type of patients are around 71% of total breast cancer patients, which shows Ibrance has largest share than Perjeta.
North America is expected to dominate the market
On the basis of regions, the blockbuster oncology brands market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to favorable regulatory bodies and huge availability of approved blockbuster oncology brands. Moreover, with increasing expenditure capacity, the response for increasing treatment price is anticipated to drive the region as compared to other regions.
Segments Covered in the Report
The global blockbuster oncology brands market has been segmented on the basis of
Key players competing in the blockbuster oncology brands market include Bristol Myers Squibb.; Merck& Co.; Pfizer, Inc.; Roche, Ltd; AstraZeneca Plc.; and Tesaro, Inc.
Many major market players are adopting several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Some other reports from this category!